{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T14:57:30Z","timestamp":1787065050498,"version":"build-2736575974"},"reference-count":15,"publisher":"Springer Science and Business Media LLC","issue":"8","license":[{"start":{"date-parts":[[2026,5,19]],"date-time":"2026-05-19T00:00:00Z","timestamp":1779148800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,7,10]],"date-time":"2026-07-10T00:00:00Z","timestamp":1783641600000},"content-version":"vor","delay-in-days":52,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100004770","name":"Universit\u00e0 degli Studi di Parma","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100004770","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ann Hematol"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    The presence of chromosome 1 abnormalities in multiple myeloma (MM) has been included in the more recent prognostic staging system; however, the prognostic role of chromosome 1 abnormalities remains controversial. Thus, in this study we have investigated the prognostic role of chromosome 1 abnormalities in a cohort of newly diagnosed MM (NDMM), performing a retrospective monocentric analysis of 95 patients. Median follow up was 66 months for overall survival (OS) and progression free survival (PFS), and 55 months for time to next treatment (TTNT). Univariate analyses showed that 1q gain or amplification did not significantly affect outcomes (OS\n                    <jats:italic>p<\/jats:italic>\n                    =0.30; PFS\n                    <jats:italic>p<\/jats:italic>\n                    =0.69; TTNT\n                    <jats:italic>p<\/jats:italic>\n                    =0.91). Conversely, del(1p) was associated with inferior OS (\n                    <jats:italic>p<\/jats:italic>\n                    =0.015), PFS (\n                    <jats:italic>p<\/jats:italic>\n                    =0.007), and TTNT (\n                    <jats:italic>p<\/jats:italic>\n                    =0.038), although this effect did not persist in multivariable models. Notably, the co occurrence of del(1p) and del(17p) identified a subgroup with markedly worse prognosis across all endpoints and represented the only combination with a consistent additive adverse effect. Multivariable analyses confirmed that patients harboring both abnormalities had significantly poorer outcomes, including reduced OS (HR 6.97, 95% CI 2.94\u201316.54), PFS (HR 6.92, 95% confidence interval [CI] 2.89\u201316.55), and TTNT (HR 5.21, 95% CI 1.69\u201316.05. In conclusion, our study suggests that among the cytogenetic abnormalities, del(1p) is a significant negative prognostic factor in NDMM patients in combination with the presence of del(17p), in shaping the prognosis of NDMM.\n                  <\/jats:p>","DOI":"10.1007\/s00277-026-07072-3","type":"journal-article","created":{"date-parts":[[2026,5,19]],"date-time":"2026-05-19T03:06:54Z","timestamp":1779160014000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Long-term prognostic impact of chromosome 1 abnormalities in newly diagnosed multiple myeloma patients: a monocentric study"],"prefix":"10.1007","volume":"105","author":[{"given":"Nicolas Thomas","family":"Iannozzi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gabriella","family":"Sammarelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea","family":"Poletti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giannalisa","family":"Todaro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matia","family":"Bernardi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matteo","family":"Scita","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna Benedetta Dalla","family":"Palma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vincenzo","family":"Raimondi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Oxana","family":"Lungu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eleonora","family":"Carboni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefania","family":"Ricci","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Camilla","family":"Sitzia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mattia","family":"Dessena","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rosanna","family":"Vescovini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Denise","family":"Toscani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paola","family":"Storti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicola","family":"Giuliani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,5,19]]},"reference":[{"key":"7072_CR1","doi-asserted-by":"publisher","first-page":"17046","DOI":"10.1038\/nrdp.2017.46","volume":"3","author":"SK Kumar","year":"2017","unstructured":"Kumar SK et al (2017) Multiple myeloma. Nat Rev Dis Primers 3:17046","journal-title":"Nat Rev Dis Primers"},{"issue":"29","key":"7072_CR2","doi-asserted-by":"publisher","first-page":"3406","DOI":"10.1200\/JCO.21.02614","volume":"40","author":"M D\u2019Agostino","year":"2022","unstructured":"D\u2019Agostino M et al (2022) Second Revision of the International Staging System (R2-ISS) for Overall Survival in Multiple Myeloma: A European Myeloma Network (EMN) Report Within the HARMONY Project. J Clin Oncol 40(29):3406\u20133418","journal-title":"J Clin Oncol"},{"issue":"24","key":"7072_CR3","doi-asserted-by":"publisher","first-page":"2739","DOI":"10.1200\/JCO-24-01893","volume":"43","author":"H Avet-Loiseau","year":"2025","unstructured":"Avet-Loiseau H et al (2025) International Myeloma Society\/International Myeloma Working Group Consensus Recommendations on the Definition of High-Risk Multiple Myeloma. J Clin Oncol 43(24):2739\u20132751","journal-title":"J Clin Oncol"},{"issue":"1","key":"7072_CR4","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1038\/s41408-024-00985-0","volume":"14","author":"K Neupane","year":"2024","unstructured":"Neupane K et al (2024) Alterations in chromosome 1q in multiple myeloma randomized clinical trials: a systematic review. Blood Cancer J 14(1):20","journal-title":"Blood Cancer J"},{"issue":"10","key":"7072_CR5","doi-asserted-by":"publisher","first-page":"2754","DOI":"10.3324\/haematol.2021.278888","volume":"106","author":"N Weinhold","year":"2021","unstructured":"Weinhold N et al (2021) Chromosome 1q21 abnormalities refine outcome prediction in patients with multiple myeloma - a meta-analysis of 2,596 trial patients. Haematologica 106(10):2754\u20132758","journal-title":"Haematologica"},{"issue":"7","key":"7072_CR6","doi-asserted-by":"publisher","first-page":"2043","DOI":"10.1038\/s41375-020-01096-y","volume":"35","author":"J Croft","year":"2021","unstructured":"Croft J et al (2021) Copy number evolution and its relationship with patient outcome-an analysis of 178 matched presentation-relapse tumor pairs from the Myeloma XI trial. Leukemia 35(7):2043\u20132053","journal-title":"Leukemia"},{"issue":"9","key":"7072_CR7","doi-asserted-by":"publisher","first-page":"1142","DOI":"10.1002\/ajh.26639","volume":"97","author":"E Kastritis","year":"2022","unstructured":"Kastritis E et al (2022) Chromosome 1q21 aberrations identify ultra high-risk myeloma with prognostic and clinical implications. Am J Hematol 97(9):1142\u20131149","journal-title":"Am J Hematol"},{"issue":"15","key":"7072_CR8","doi-asserted-by":"publisher","first-page":"3509","DOI":"10.1182\/bloodadvances.2020002218","volume":"4","author":"N Abdallah","year":"2020","unstructured":"Abdallah N et al (2020) Clinical characteristics and treatment outcomes of newly diagnosed multiple myeloma with chromosome 1q abnormalities. Blood Adv 4(15):3509\u20133519","journal-title":"Blood Adv"},{"issue":"11","key":"7072_CR9","doi-asserted-by":"publisher","first-page":"1308","DOI":"10.1182\/blood.2022017863","volume":"141","author":"A Schavgoulidze","year":"2023","unstructured":"Schavgoulidze A et al (2023) Biallelic deletion of 1p32 defines ultra-high-risk myeloma, but monoallelic del(1p32) remains a strong prognostic factor. Blood 141(11):1308\u20131315","journal-title":"Blood"},{"issue":"Supplement 1","key":"7072_CR10","doi-asserted-by":"publisher","first-page":"2024","DOI":"10.1182\/blood-2023-190728","volume":"142","author":"E Jurgens","year":"2023","unstructured":"Jurgens E et al (2023) Clinical Outcomes Associated with Del(17p) in Newly Diagnosed Multiple Myeloma Treated with Triplet and Daratumumab-Based Quadruplet Induction Regimens. Blood 142(Supplement 1):2024\u20132024","journal-title":"Blood"},{"issue":"11","key":"7072_CR11","doi-asserted-by":"publisher","first-page":"1217","DOI":"10.1182\/blood-2018-10-880831","volume":"133","author":"A Thakurta","year":"2019","unstructured":"Thakurta A et al (2019) High subclonal fraction of 17p deletion is associated with poor prognosis in multiple myeloma. Blood 133(11):1217\u20131221","journal-title":"Blood"},{"issue":"11","key":"7072_CR12","doi-asserted-by":"publisher","first-page":"2034","DOI":"10.1038\/sj.leu.2404403","volume":"20","author":"R Fonseca","year":"2006","unstructured":"Fonseca R et al (2006) Prognostic value of chromosome 1q21 gain by fluorescent in situ hybridization and increase CKS1B expression in myeloma. Leukemia 20(11):2034\u20132040","journal-title":"Leukemia"},{"issue":"12","key":"7072_CR13","doi-asserted-by":"publisher","first-page":"94","DOI":"10.1038\/s41408-019-0254-0","volume":"9","author":"TM Schmidt","year":"2019","unstructured":"Schmidt TM et al (2019) Gain of Chromosome 1q is associated with early progression in multiple myeloma patients treated with lenalidomide, bortezomib, and dexamethasone. Blood Cancer J 9(12):94","journal-title":"Blood Cancer J"},{"issue":"7","key":"7072_CR14","doi-asserted-by":"publisher","first-page":"1150","DOI":"10.3324\/haematol.2009.016436","volume":"95","author":"K Neben","year":"2010","unstructured":"Neben K et al (2010) Combining information regarding chromosomal aberrations t(4;14) and del(17p13) with the International Staging System classification allows stratification of myeloma patients undergoing autologous stem cell transplantation. Haematologica 95(7):1150\u20131157","journal-title":"Haematologica"},{"issue":"2","key":"7072_CR15","doi-asserted-by":"publisher","first-page":"353","DOI":"10.3324\/haematol.2013.088211","volume":"99","author":"G An","year":"2014","unstructured":"An G et al (2014) Chromosome 1q21 gains confer inferior outcomes in multiple myeloma treated with bortezomib but copy number variation and percentage of plasma cells involved have no additional prognostic value. Haematologica 99(2):353\u2013359","journal-title":"Haematologica"}],"container-title":["Annals of Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00277-026-07072-3","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-026-07072-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-026-07072-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,15]],"date-time":"2026-08-15T09:20:17Z","timestamp":1786785617000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00277-026-07072-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,19]]},"references-count":15,"journal-issue":{"issue":"8","published-online":{"date-parts":[[2026,8]]}},"alternative-id":["7072"],"URL":"https:\/\/doi.org\/10.1007\/s00277-026-07072-3","relation":{},"ISSN":["1432-0584"],"issn-type":[{"value":"1432-0584","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,19]]},"assertion":[{"value":"11 March 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 May 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 May 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Nicola Giuliani received research funding from Pfizer and honoraria from Amgen, Sanofi, Bristol-Myers Squibb, GSK.","order":1,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"325"}}